E. Saygili, U. Devamoglu, B. Goker-Bagca, O. Goksel, C. Biray-Avci, T. Goksel, O. Yesil‐Celiktas
{"title":"药物反应性多细胞人球体模型重现药物性肺纤维化","authors":"E. Saygili, U. Devamoglu, B. Goker-Bagca, O. Goksel, C. Biray-Avci, T. Goksel, O. Yesil‐Celiktas","doi":"10.1088/1748-605X/ac73cd","DOIUrl":null,"url":null,"abstract":"Associated with a high mortality rate, pulmonary fibrosis (PF) is the end stage of several interstitial lung diseases. Although many factors are linked to PF progression, initiation of the fibrotic process remains to be studied. Current research focused on generating new strategies to gain a better understanding of the underlying disease mechanism as the animal models remain insufficient to reflect human physiology. Herein, to account complex cellular interactions within the fibrotic tissue, a multicellular spheroid model where human bronchial epithelial cells incorporated with human lung fibroblasts was generated and treated with bleomycin (BLM) to emulate drug-induced PF. Recapitulating the epithelial-interstitial microenvironment, the findings successfully reflected the PF disease, where excessive alpha smooth muscle actin and collagen type I secretion were noted along with the morphological changes in response to BLM. Moreover, increased levels of fibrotic linked COL13A1, MMP2, WNT3 and decreased expression level of CDH1 provide evidence for the model reliability on fibrosis modelling. Subsequent administration of the Food and Drug Administration approved nintedanib and pirfenidone anti-fibrotic drugs proved the drug-responsiveness of the model.","PeriodicalId":9016,"journal":{"name":"Biomedical materials","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A drug-responsive multicellular human spheroid model to recapitulate drug-induced pulmonary fibrosis\",\"authors\":\"E. Saygili, U. Devamoglu, B. Goker-Bagca, O. Goksel, C. Biray-Avci, T. Goksel, O. Yesil‐Celiktas\",\"doi\":\"10.1088/1748-605X/ac73cd\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Associated with a high mortality rate, pulmonary fibrosis (PF) is the end stage of several interstitial lung diseases. Although many factors are linked to PF progression, initiation of the fibrotic process remains to be studied. Current research focused on generating new strategies to gain a better understanding of the underlying disease mechanism as the animal models remain insufficient to reflect human physiology. Herein, to account complex cellular interactions within the fibrotic tissue, a multicellular spheroid model where human bronchial epithelial cells incorporated with human lung fibroblasts was generated and treated with bleomycin (BLM) to emulate drug-induced PF. Recapitulating the epithelial-interstitial microenvironment, the findings successfully reflected the PF disease, where excessive alpha smooth muscle actin and collagen type I secretion were noted along with the morphological changes in response to BLM. Moreover, increased levels of fibrotic linked COL13A1, MMP2, WNT3 and decreased expression level of CDH1 provide evidence for the model reliability on fibrosis modelling. Subsequent administration of the Food and Drug Administration approved nintedanib and pirfenidone anti-fibrotic drugs proved the drug-responsiveness of the model.\",\"PeriodicalId\":9016,\"journal\":{\"name\":\"Biomedical materials\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2022-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical materials\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1088/1748-605X/ac73cd\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1088/1748-605X/ac73cd","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
A drug-responsive multicellular human spheroid model to recapitulate drug-induced pulmonary fibrosis
Associated with a high mortality rate, pulmonary fibrosis (PF) is the end stage of several interstitial lung diseases. Although many factors are linked to PF progression, initiation of the fibrotic process remains to be studied. Current research focused on generating new strategies to gain a better understanding of the underlying disease mechanism as the animal models remain insufficient to reflect human physiology. Herein, to account complex cellular interactions within the fibrotic tissue, a multicellular spheroid model where human bronchial epithelial cells incorporated with human lung fibroblasts was generated and treated with bleomycin (BLM) to emulate drug-induced PF. Recapitulating the epithelial-interstitial microenvironment, the findings successfully reflected the PF disease, where excessive alpha smooth muscle actin and collagen type I secretion were noted along with the morphological changes in response to BLM. Moreover, increased levels of fibrotic linked COL13A1, MMP2, WNT3 and decreased expression level of CDH1 provide evidence for the model reliability on fibrosis modelling. Subsequent administration of the Food and Drug Administration approved nintedanib and pirfenidone anti-fibrotic drugs proved the drug-responsiveness of the model.
期刊介绍:
The goal of the journal is to publish original research findings and critical reviews that contribute to our knowledge about the composition, properties, and performance of materials for all applications relevant to human healthcare.
Typical areas of interest include (but are not limited to):
-Synthesis/characterization of biomedical materials-
Nature-inspired synthesis/biomineralization of biomedical materials-
In vitro/in vivo performance of biomedical materials-
Biofabrication technologies/applications: 3D bioprinting, bioink development, bioassembly & biopatterning-
Microfluidic systems (including disease models): fabrication, testing & translational applications-
Tissue engineering/regenerative medicine-
Interaction of molecules/cells with materials-
Effects of biomaterials on stem cell behaviour-
Growth factors/genes/cells incorporated into biomedical materials-
Biophysical cues/biocompatibility pathways in biomedical materials performance-
Clinical applications of biomedical materials for cell therapies in disease (cancer etc)-
Nanomedicine, nanotoxicology and nanopathology-
Pharmacokinetic considerations in drug delivery systems-
Risks of contrast media in imaging systems-
Biosafety aspects of gene delivery agents-
Preclinical and clinical performance of implantable biomedical materials-
Translational and regulatory matters